PImmunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2

  • Authors: Pierpaolo Correale, Stefania Marsili, Marianna Sabatino, Francesco Montagnani, Giorgio Giorgi, Guido Francini
  • View Affiliations

  • Published online on: Friday, April 1, 2005
  • Pages: 751-756
  • DOI: 10.3892/or.13.4.751

Abstract

We have performed a translational phase II trial testing an original immunotherapy schedule based on the monthly subcutaneous (s.c.) administration of hrGM-CSF (days 1 through 5) and very low dose hrIL-2 (days 6 through 15) in 19 patients with metastatic renal cell carcinoma. Bone pain, first dose reaction to GM-CSF, asthenia and fever were the most common side effects. A partial response, and a disease stabilization were respectively observed in 4 and 11 cases, with a rate of objective response and a disease control rate respectively of 21% and 79%. We recorded a time to progression of 9 months and a 2- and 3-year survival respectively of 42% (8/19 patients) and 26% (5/19 patients). Our results suggest that this GM-CSF/hrIL-2 combination is active and well tolerated in patients with renal cell carcinoma and deserves to be investigated in larger comparative trials.
Journal Cover

April 2005
Volume 13 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

2013 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Correale, P., Marsili, S., Sabatino, M., Montagnani, F., Giorgi, G., & Francini, G. (2005). PImmunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2. Oncology Reports, 13(4), 751-756.
MLA
Correale, Marsili, Sabatino, Montagnani, Giorgi, and Guido Francini. "PImmunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2." Oncology Reports Oncology Reports 13.4 (2005): 751-756.
Chicago
Correale, Marsili, Sabatino, Montagnani, Giorgi, and Guido Francini. "PImmunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2." Oncology Reports Oncology Reports 13 no. 4 (2005): 751-756.